Rights and permissions
About this article
Cite this article
Moxifloxacin IV-to-oral switch proves cost effective in patients with CAP. Pharmacoecon. Outcomes News 368, 7–8 (2002). https://doi.org/10.1007/BF03279230
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03279230